|Bid||152.010 x 200|
|Ask||152.400 x 200|
|Day's Range||151.300 - 155.200|
|52 Week Range||95.080 - 170.300|
|PE Ratio (TTM)||194.50|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||151.67|
Ligand's (LGND) earnings and revenues beat estimates. The top line also rises year over year owing to higher royalty benefits. The company provides a strong 2018 guidance.
The San Diego-based company said it had a loss of 33 cents per share. Earnings, adjusted for one-time gains and costs, were $1.31 per share. The drugmaker posted revenue of $50.5 million in the period, ...
Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2017, and provided an operating forecast and program updates.
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018, ...
On Wednesday, Ligand Pharmaceuticals (NASDAQ: LGND ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Based on Ligand management projections, analysts ...
Novartis: What Are the Major Growth Drivers for 2018? Novartis’s (NVS) Promacta reported sales if $255 million in 4Q17, which is a year-over-year (or YoY) rise of 43.0% on a constant currency basis. On January 4, 2018, Novartis announced that the FDA granted breakthrough therapy designation to the combination of Promacta and immunosuppressive therapy.
Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
NEW YORK, Feb. 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of A. ...
Ligand Pharmaceuticals Incorporated announced today plans to report fourth quarter and full year 2017 financial results on February 21, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
With the market up 22% up over the course of the past year, led by giants like Amazon.com, Inc. (NASDAQ:AMZN) and Facebook, Inc. (NASDAQ:FB), investors might fear that a pullback is just around the corner. If you’d rather not start that search one your own, here’s a look at ten small-cap stocks to buy. As with all risky investments, these small-cap stocks to buy have to be kept on a short leash and require plenty of monitoring.
Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
Good stocks that are on a solid growth path will help you remain cool while crypto investors are watching every uptick and downtick. Caterpillar Inc (NYSE: CAT) is the 800-pound gorilla of the heavy-duty machinery business. For the past decade, CAT stock has been floundering because there wasn’t much growth, so there was no demand for equipment.
Ligand Pharmaceuticals Incorporated announces initiation of a program to develop contrast agents with reduced renal toxicity. Contrast agents are injectable solutions used during diagnostic imaging procedures.
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.
Stocks continued to evaporate gains in afternoon trading Tuesday, while the Russell 2000 small-cap index reversed lower.
Ligand Pharmaceuticals Incorporated announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken™, OmniRat®, OmniMouse® and OmniFlic® to discover fully human mono- and multispecific antibodies.
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.